Investor directory

Action Potential Venture Capital

Action Potential Venture Capital is a strategic venture capital fund launched by GlaxoSmithKline with an initial commitment of $50 million. Based in Cambridge, Massachusetts, the fund aims to invest in companies that develop bioelectronic medicines and technologies. It plans to build a portfolio of five to seven companies over the next five years, focusing on three areas: new start-ups pursuing bioelectronic medicine, existing companies with technologies that interact with the peripheral nervous system through first-generation devices, and companies enhancing technology platforms for these treatments. The fund's name reflects the electrical signals, known as action potentials, that travel along nerves, which can be linked to various diseases. The first investment was made in SetPoint Medical, a leader in implantable devices for inflammatory diseases. The fund is managed by a dedicated team, with Imran Eba as its first partner, who will collaborate closely with GlaxoSmithKline's Bioelectronics R&D unit to drive advancements in this emerging field.
http://www.actionpotentialvc.com
https://crunchbase.com/organization/action-potential-venture-capital
https://linkedin.com/company/9130275
https://signal.nfx.com/firms/action-potential-venture-capital

Imran Eba

Partner

Juan-Pablo Mas

Partner

16 past transactions

Saluda Medical

Venture Round in 2023
Saluda Medical Pty Ltd., established in 2013 and headquartered in Artarmon, Australia, focuses on developing innovative medical devices for the neuromodulation industry. The company's flagship product, Evoke, is an investigational closed-loop spinal cord stimulation system designed to measure and adapt to the spinal cord's response to stimulation. By adjusting the stimulation on every pulse, Evoke aims to optimize therapeutic outcomes for patients within their individualized treatment parameters. Saluda Medical's foundation is built on years of research from Australia's NICTA and is supported by a team of experienced engineers, clinicians, and professionals dedicated to advancing medical technologies. The company also has offices in Bloomington, Minnesota, and Harrogate, United Kingdom.

MicroTransponder

Series E in 2022
MicroTransponder, Inc. is a medical device company focused on developing and commercializing neurostimulation devices aimed at treating neurological diseases. The company offers innovative therapies, including the Serenity System for tinnitus and the Paired VNS System, which addresses chronic pain and post-stroke upper limb mobility issues. Founded in 2007, MicroTransponder is headquartered in Dallas, Texas, and aims to enhance treatment options for various neurological conditions through its advanced technology.

Alpheus Medical

Series A in 2021
Alpheus Medical provides a novel sonodynamic therapy platform targeting solid body cancers. Alpheus Medical also provides a non-invasive drug-device combination for outpatient treatment of recurrent glioblastoma multiforme (rGBM).

NeuSpera Medical

Series C in 2021
NeuSpera Medical Inc. develops and manufactures ultra-miniaturized implantable devices for neuromodulation therapy. Its Neuspera Mid-Field Powering technology uses the body as a natural waveguide to direct energy. NeuSpera Medical Inc. was formerly known as Vivonda Medical Incorporated. The company was incorporated in 2013 and is based in San Jose, California.

Exo

Series B in 2020
Exo is a medical device startup handheld ultrasound platform and AI for imaging and therapeutic applications. The company is committed to delivering affordable and easy-to-use medical imaging to healthcare professionals around the world. By delivering easy-to-use, high-quality medical imaging. Exo empowers healthcare professionals to make critical, real-time decisions that improve patient outcomes. The Exo ultrasound platform combines advances in nano-materials, novel sensor technologies, advanced signal processing, and computation with the economies of scale of semiconductor manufacturing to dramatically reduce the cost of imaging. It also represents a giant leap in imaging and therapeutics technology one that will drive the development of high-performance products that are accessible, easy-to-use, and available at a price point never before possible.

CVRx

Venture Round in 2020
CVRx is a medical device company that develops implantable technology for the treatment of high blood pressure. Its products include Rheos implantable pulse generator that provides control and delivery of the activation energy; and Rheos carotid sinus leads, which conducts activation energy from the Rheos implantable pulse generator to the left and right carotid arteries. The company also offers a Rheos programmer system that communicates with the Rheos pulse generator. CVRx was founded in 2001 and is based in Minneapolis, Minnesota.

SetPoint Medical

Venture Round in 2019
SetPoint Medical Corporation, a clinical-stage bioelectronic medicine company, develops implantable neuromodulation devices for treating patients with debilitating inflammatory diseases. SetPoint Medical Corporation was formerly known as Innovative Metabolics Inc. and changed its name to SetPoint Medical Corporation in July 2008. The company was incorporated in 2006 and is based in Valencia, California.

CVRx

Series G in 2019
CVRx is a medical device company that develops implantable technology for the treatment of high blood pressure. Its products include Rheos implantable pulse generator that provides control and delivery of the activation energy; and Rheos carotid sinus leads, which conducts activation energy from the Rheos implantable pulse generator to the left and right carotid arteries. The company also offers a Rheos programmer system that communicates with the Rheos pulse generator. CVRx was founded in 2001 and is based in Minneapolis, Minnesota.

NeuSpera Medical

Series B in 2019
NeuSpera Medical Inc. develops and manufactures ultra-miniaturized implantable devices for neuromodulation therapy. Its Neuspera Mid-Field Powering technology uses the body as a natural waveguide to direct energy. NeuSpera Medical Inc. was formerly known as Vivonda Medical Incorporated. The company was incorporated in 2013 and is based in San Jose, California.

NeuSpera Medical

Series B in 2018
NeuSpera Medical Inc. develops and manufactures ultra-miniaturized implantable devices for neuromodulation therapy. Its Neuspera Mid-Field Powering technology uses the body as a natural waveguide to direct energy. NeuSpera Medical Inc. was formerly known as Vivonda Medical Incorporated. The company was incorporated in 2013 and is based in San Jose, California.

SetPoint Medical

Series D in 2017
SetPoint Medical Corporation, a clinical-stage bioelectronic medicine company, develops implantable neuromodulation devices for treating patients with debilitating inflammatory diseases. SetPoint Medical Corporation was formerly known as Innovative Metabolics Inc. and changed its name to SetPoint Medical Corporation in July 2008. The company was incorporated in 2006 and is based in Valencia, California.

Saluda Medical

Series D in 2017
Saluda Medical Pty Ltd., established in 2013 and headquartered in Artarmon, Australia, focuses on developing innovative medical devices for the neuromodulation industry. The company's flagship product, Evoke, is an investigational closed-loop spinal cord stimulation system designed to measure and adapt to the spinal cord's response to stimulation. By adjusting the stimulation on every pulse, Evoke aims to optimize therapeutic outcomes for patients within their individualized treatment parameters. Saluda Medical's foundation is built on years of research from Australia's NICTA and is supported by a team of experienced engineers, clinicians, and professionals dedicated to advancing medical technologies. The company also has offices in Bloomington, Minnesota, and Harrogate, United Kingdom.

Cala Health

Series B in 2016
Cala Health is a bioelectronic medicine company focused on improving the treatment of chronic diseases through innovative neuromodulation therapies. The company specializes in wearable devices that provide individualized peripheral nerve stimulation, aiming to alleviate symptoms for patients with conditions such as essential tremor, which affects millions globally. Its primary product, Cala Trio, is a non-invasive therapy designed to offer transient relief from hand tremors in adults suffering from this condition. In addition to its current offerings, Cala Health is expanding its research and development efforts into therapies for neurology, cardiology, and psychiatry. Founded in 2013 and based in the San Francisco Bay Area, Cala Health is supported by prominent investors in healthcare and technology.

SetPoint Medical

Series C in 2015
SetPoint Medical Corporation, a clinical-stage bioelectronic medicine company, develops implantable neuromodulation devices for treating patients with debilitating inflammatory diseases. SetPoint Medical Corporation was formerly known as Innovative Metabolics Inc. and changed its name to SetPoint Medical Corporation in July 2008. The company was incorporated in 2006 and is based in Valencia, California.

SetPoint Medical

Series C in 2013
SetPoint Medical Corporation, a clinical-stage bioelectronic medicine company, develops implantable neuromodulation devices for treating patients with debilitating inflammatory diseases. SetPoint Medical Corporation was formerly known as Innovative Metabolics Inc. and changed its name to SetPoint Medical Corporation in July 2008. The company was incorporated in 2006 and is based in Valencia, California.